AMARILLO, Texas, June 11 /PRNewswire-FirstCall/ -- Amarillo Biosciences,
Inc. (OTC Bulletin Board: AMAR) announces supply agreements with STC
International (East Brunswick, New Jersey) for the territories of China and
Taiwan and with Majsons Corporation (Karachi) for the territory of Pakistan.
Maxisal(TM), a patented dietary supplement, is the trade name for
pharmaceutical grade anhydrous crystalline maltose, which has been found to
relieve complaints of dry mouth, enhance salivary function, and promote oral
comfort. Amarillo Biosciences, Inc. is the exclusive worldwide (outside
Japan) supplier of Maxisal(TM) for the dry mouth market.
Dr. Joseph M. Cummins, President and CEO of Amarillo Biosciences, Inc.
said, "We are very pleased that Maxisal(TM) will be sold by our new
distributors in their respective territories. Researchers estimate that at
least 20% of the population over 50 years of age suffer from persistent
complaints of dry mouth. The number of people with dry mouth is even greater
if you include people who suffer from autoimmune diseases or take one of the
many prescription medications that cause dry mouth."
Dr. Cummins concluded, "Our innovative, new product will enable us to
continue to take advantage of the many growth opportunities in the
biotechnology market. We believe this dry mouth market is poised for
significant growth."
About Amarillo Biosciences, Inc.
Amarillo Biosciences, Inc. is a pioneer in the research of low-dose orally
administered interferon alpha as a treatment for a variety of conditions
including Sjogren's syndrome, fibromyalgia syndrome, Behcet's disease,
hepatitis B and C, and opportunistic infections in patients who are HIV
positive. Additional information is available on the Amarillo Biosciences,
Inc. web site at http://www.amarbio.com .
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including uncertainties related to product
development, uncertainties related to the need for regulatory and other
government approvals, dependence on proprietary technology, uncertainty of
market acceptance of oral interferon alpha or the Company's other product
candidates and other risks detailed from time to time in the Company's filings
with the Securities and Exchange Commission. In particular, see "Item 1.
Description of Business" of the Company's Form 10-KSB for the year ended
December 31, 2001.
SOURCE Amarillo Biosciences, Inc.
 back to top
Related links:
http://www.amarbio.com
Company News On-Call:
http://www.prnewswire.com/comp/118055.html
CONTACT:
Dr. Joseph M. Cummins, President & CEO of
Amarillo Biosciences, Inc., +1-806-376-1741, ext. 13
|
